Pirtobrutinib Approval Adds Effective Third-Line Option to Previously Treated CLL/SLL Armamentarium

Lori A. Leslie, MD, discusses the significance of the FDA approval of pirtobrutinib for this population alongside the unmet needs it may address, highlights the efficacy and notable toxicities seen with the agent in the BRUIN study, and expands on the continued investigation of pirtobrutinib vs other standard-of-care regimens in various CLL subtypes.

Related Keywords

United States ,Hackensack ,New Jersey ,Eli Lilly ,Gloria Leslie ,Hackensack Meridian School Of Medicine ,National Comprehensive Cancer Network ,Hackensack Meridian Health ,Indolent Lymphoma ,Chronic Lymphocytic Leukemia Research Programs ,John Theurer Cancer Center ,Hackensack Meridian School ,Hackensack Meridian ,Cart Cell Therapy ,D ,John Theurer Cancer Center Of Hackensack Meridian Health ,Pirtobrutinib ,Third Line ,Cll ,Usll ,